RARE

Ultragenyx Pharmaceutical Inc. (RARE) - 10-K Summary

Business Context and Reporting Period

Company: Ultragenyx Pharmaceutical Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: A biopharmaceutical company focused on developing and commercializing novel therapies for serious rare and ultra-rare genetic diseases. The portfolio includes four approved products (Crysvita, Mepsevii, Dojolvi, Evkeeza) and a pipeline of gene therapies and nucleic acid candidates.

Key Financial Metrics (Year Ended Dec 31, 2025)

Note: The filing text does not provide explicit gross margin percentages; however, Cost of Sales was $109 million in 2025 compared to $77 million in 2024.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 20% to $673 million, driven by higher demand for Crysvita (31% increase in product sales) and Evkeeza (84% increase in product sales). Crysvita royalty revenue also rose 11% to $304 million.
• Expense Increases: R&D expenses increased 7% to $750 million, primarily due to increased manufacturing costs for UX111 (Sanfilippo syndrome) and continued clinical development of UX143 and GTX-102. SG&A increased 9% due to higher compensation and marketing expenses.
• Financing Activity: The company raised $392 million in November 2025 from the sale of future royalties to OMERS and $80 million via an At-The-Market (ATM) offering.
• Stock Performance: The stock price declined significantly over the five-year period, with a $100 investment in 2020 valued at $16.61 by December 31, 2025.

Guidance, Outlook, and Risks

• Profitability Outlook: Management expects to achieve profitability in 2027, though this is subject to assumptions regarding regulatory approvals and commercialization success.
• Restructuring Plan: In February 2026, the company initiated a strategic restructuring plan involving a 10% workforce reduction (approx. 130 employees) and estimated charges of $50 million to reduce expenses and align with pipeline requirements.
• Key Pipeline Updates:
  • UX111 (MPS IIIA): Received an Incomplete Response Letter (IRL) from the FDA in February 2026 regarding a resubmitted BLA; additional documentation is required.
  • DTX401 (GSDIa): Rolling BLA submission completed in December 2025; PDUFA action date expected in Q3 2026.
  • UX143 (Osteogenesis Imperfecta): Phase 3 studies (Orbit and Cosmic) failed to achieve primary endpoints in December 2025. The company is analyzing data for a potential path forward.
• Major Risks:
  • Regulatory Uncertainty: Delays or denials for key product candidates (UX111, DTX401) could materially impact future revenue.
  • Commercialization Dependency: Heavy reliance on partner Kyowa Kirin (KKC) for Crysvita supply and commercialization in major markets (U.S., Canada, Europe).
  • Generic Competition: Ongoing litigation regarding generic versions of Dojolvi (triheptanoin).
  • Liquidity: While cash resources are sufficient for 12+ months, continued losses may necessitate additional capital raises.

Investor Verification Checklist

• UX111 Regulatory Status: Verify the timeline for resubmitting the BLA following the February 2026 IRL and the specific CMC responses required by the FDA.
• UX143 Path Forward: Confirm if the company will abandon the program or pursue alternative indications/dosing regimens following the Phase 3 failure.
• Restructuring Execution: Monitor the realization of the anticipated $50 million in restructuring charges and the actual cost savings achieved from the 10% workforce reduction.
• Dojolvi Litigation: Track the status of the patent infringement suits against Navinta, Aurobindo, and Esjay regarding generic entry.
• DTX401 Approval: Watch for the PDUFA date in Q3 2026 and the likelihood of approval for the GSDIa gene therapy.
• Capital Needs: Assess the burn rate relative to the $737 million cash position to determine if additional equity or royalty sales will be required before 2027.